Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 4Recurrence 2Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Klatskin Tumor 1Hematologic Neoplasms 1Hematologic Diseases 1Fallopian Tube Neoplasms 1Disease Progression 1Disease 1Cholangiocarcinoma 1Breast Neoplasms 1Blood Protein Disorders 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 40Cisplatin 24Capecitabine 21Fluorouracil 19Oxaliplatin 17Leucovorin 14pembrolizumab 9Irinotecan 8Radiotherapy 7Erlotinib Hydrochloride 7durvalumab 6Sorafenib 4Magnetic Resonance Spectroscopy 4Carboplatin 4trametinib 3Trastuzumab 3Photochemotherapy 3Long-Term Synaptic Depression 3Interleukin-12 Subunit p35 3Filgrastim 3Dihematoporphyrin Ether 3Dexamethasone 3Chemotherapy, Adjuvant 3trifluridine tipiracil drug combination 2tivozanib 2tislelizumab 2spartalizumab 2regorafenib 2olaparib 2dehydroftorafur 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bile Duct Neoplasms × ricolinostat × Clear all
NCT02856568 2017-05-30

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡